Association between the triglyceride glucose-body mass index and cardiometabolic diseases risk in chronic liver disease: a nationwide cohort study.

BACKGROUND: The association between cardiometabolic diseases and the triglyceride-glucose-body mass index (TyG-BMI) has been proved. However, the relationship between the TyG-BMI and cardiometabolic complications in chronic liver disease (CLD) patients has not been clearly elucidated. We aimed to investigate whether the TyG-BMI and its trajectory are associated with cardiometabolic comorbidities, especially Cardiovascular-Kidney-Metabolic syndrome (CKM) in patients with CLD. METHODS: We obtained data from the China Health and Retirement Longitudinal Study (CHARLS) from 2011 to 2020. The exposures were baseline TyG-BMI value at baseline and its change between the first and third waves. The change in TyG-BMI was classified via dynamic time wrapping clustering. The outcomes were CKM syndrome and other cardiometabolic diseases. Adjusted Cox proportional hazards regression was used as the main statistical method. RESULTS: There were 765 participants in the CKM cohort, of whom 426 (55.7%) were male and 339 (44.3%) were female. High baseline TyG-BMI values were associated with an HR (95% CI) of 2.404 (1.889-3.060; P < 0.001) for CKM. Compared with those in the steadily low TyG-BMI group, the HR (95%CI) in the steadily high TyG-BMI group was 1.405 (1.051-1.879; P = 0.022), the HR (95% CI) in the increasing TyG-BMI group was 1.602 (1.154-2.223; P = 0.005). Results in other cohorts also confirm the relationship between TyG-BMI and CKM-related diseases. CONCLUSION: Baseline high levels and steadily high or increasing high levels of TyG-BMI are associated with cardiometabolic diseases in CLD patients. Monitoring TyG-BMI might improve the prognosis of patients with CLD.